In the latest trading session, 0.48 million Stoke Therapeutics Inc (NASDAQ:STOK) shares changed hands as the company’s beta touched 0.95. With the company’s most recent per share price at $8.45 changed hands at -$0.55 or -6.11% at last look, the market valuation stands at $447.57M. STOK’s current price is a discount, trading about -108.05% off its 52-week high of $17.58. The share price had its 52-week low at $5.60, which suggests the last value was 33.73% up since then. When we look at Stoke Therapeutics Inc’s average trading volume, we note the 10-day average is 0.61 million shares, with the 3-month average coming to 805.70K.
Analysts gave the Stoke Therapeutics Inc (STOK) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended STOK as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Stoke Therapeutics Inc’s EPS for the current quarter is expected to be -0.52.
Stoke Therapeutics Inc (NASDAQ:STOK) trade information
Instantly STOK was in red as seen in intraday trades today. With action 3.05%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -23.39%, with the 5-day performance at 3.05% in the green. However, in the 30-day time frame, Stoke Therapeutics Inc (NASDAQ:STOK) is -20.88% down. Looking at the short shares, we see there were 11.17 million shares sold at short interest cover period of 13.49 days.
The consensus price target for the stock as assigned by Wall Street analysts is 18, meaning bulls need an upside of 53.06% from its recent market value. According to analyst projections, STOK’s forecast low is 18 with 18 as the target high. To hit the forecast high, the stock’s price needs a -113.02% plunge from its current level, while the stock would need to soar -113.02% for it to hit the projected low.
Stoke Therapeutics Inc (STOK) estimates and forecasts
Year-over-year growth is forecast to reach 47.22% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 7.26M. 5 analysts are of the opinion that Stoke Therapeutics Inc’s revenue for the current quarter will be 7.26M. The company’s revenue for the corresponding quarters a year ago was 4.22M and 4.83M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 72.20%. The estimates for the next quarter sales put growth at 50.28%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -44.06%. The 2025 estimates are for Stoke Therapeutics Inc earnings to increase by 2.20%, but the outlook for the next 5-year period is at -10.89% per year.
Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.67% of Stoke Therapeutics Inc shares while 110.52% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 115.93%. There are 110.52% institutions holding the Stoke Therapeutics Inc stock share, with SKORPIOS TRUST the top institutional holder. As of 2024-06-30, the company held 19.445% of the shares, roughly 10.84 million STOK shares worth $146.5 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 11.6963% or 5.41 million shares worth $73.08 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Blackrock Funds-Health Sciences Opportunity Portfolio. With 1.57 shares estimated at $13.44 million under it, the former controlled 2.97% of total outstanding shares. On the other hand, Blackrock Funds-Health Sciences Opportunity Portfolio held about 1.83% of the shares, roughly 969.34 shares worth around $8.27 million.
